Armata Pharmaceuticals, Inc. (ARMP) News
Track canonical SquawkNews coverage tagged to ARMP, Armata Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
HC Wainwright & Co. reiterates Buy rating on Armata Pharmaceuticals, $15 price target
HC Wainwright & Co. reiterated their Buy rating on Armata Pharmaceuticals's stock with a price target of $15.00.The price target implies an upside of 257.1% from the Sep 22 close of $4.20.Key takeaways from the analyst n
EQUITY | Sep 23, 2026, 03:04 PM UTC
L
Armata Gets $3.7M in Additional Funding From Defense Dept. for Bacterial Infection Treatment
By Kelly CloonanArmata Pharmaceuticals said it received an additional $3.7 million in non-dilutive funds from the Defense Department to continue developing a treatment for a type of bacterial infection.The biotechnology
NEWS | Sep 23, 2026, 11:46 AM UTC
H
Armata Pharmaceuticals receives $3.7M in DoW funding to support AP-SA02 Phase 3
Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02.Key Highlights:Original SEC Filing: Armata Pharmaceuticals, Inc. [
GEOPOLITICS | Sep 23, 2026, 11:14 AM UTC
H
Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02
Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise Consortium ("MTEC")
LIVE | Sep 23, 2026, 11:09 AM UTC
H
ARMP - Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
ARMP - Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
GEOPOLITICS | Sep 23, 2026, 11:00 AM UTC
L
ARMP - Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
ARMP - Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
NEWS | Sep 21, 2026, 11:00 AM UTC
L
ARMP - Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
ARMP - Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 10, 2026, 11:00 AM UTC
L
ARMP - Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generati
ARMP - Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
EQUITY | Sep 03, 2026, 11:01 AM UTC
L
ARMP Announces Q2 2026 Financial Results
ARMP announces financial results for the second quarter 2026 and provides a corporate update
EARNINGS | Aug 12, 2026, 08:06 PM UTC
L
Armata Pharma Reaches FDA Agreement on Pediatric Study Plan for AP-SA02
() -- Armata Pharmaceuticals (ARMP) said Monday it has reached agreement with the US Food and Drug Administration on an agreed initial pediatric study plan for AP-SA02, clearing a regulatory requirement ahead of a potent
REGULATION | Jul 13, 2026, 11:47 AM UTC
L
Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02
Armata Pharmaceuticals...
EQUITY | Jul 13, 2026, 11:04 AM UTC
M
ARMP Receives $2.5M Funding
Armata Pharmaceuticals receives $2.5 million in non-dilutive award funding from the U.S. Department of Defense to support AP-SA02
EQUITY | Jun 23, 2026, 11:03 AM UTC